iifl-logo

Marksans Pharma Ltd Historical Data

169.39
(-0.41%)
Sep 25, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Marksans Pharma Ltd Historical Data

26/08/2025calendar-icon
26/09/2025calendar-icon
Date
Open(₹)
High(₹)
Low(₹)
Close(₹)
No. Of Trades(₹)
Total Turnover(₹)
Deliverable Quantity(₹)

28-Aug-2025

173.27

173.75169169.4720,84815,58,85,866.234,68,441

29-Aug-2025

170

172.2166.75168.621,40719,29,56,900.854,63,532

01-Sep-2025

169.4

170.61165.52167.3730,36937,33,75,438.0813,28,964

02-Sep-2025

169.9

173.77167.9170.9519,01220,75,02,5304,71,146

03-Sep-2025

172

174.99169.17173.0214,63216,33,15,912.963,72,823

04-Sep-2025

176.95

177.29169.92171.5821,57322,52,78,215.686,34,441

05-Sep-2025

171.51

174.5168.4168.9123,45332,56,30,768.149,39,989

08-Sep-2025

170.26

171.43167.71169.4918,24316,24,15,794.944,93,608

09-Sep-2025

170.85

174.216917215,48816,00,51,200.713,98,969

10-Sep-2025

173.61

177.9173.5176.924,76626,26,30,195.217,29,837

11-Sep-2025

177.45

180.21173.25174.218,80621,37,37,089.625,47,717

12-Sep-2025

175.5

176.37172.51172.9310,50911,59,04,0672,92,302

15-Sep-2025

173.01

175.12172174.4411,26311,18,70,668.522,83,591

16-Sep-2025

175

178.89173.4176.1115,61219,11,83,663.664,22,763

17-Sep-2025

177.4

180.65176.39179.2423,96124,66,57,378.466,95,563

18-Sep-2025

180.63

181.6176.71178.3716,65315,66,55,418.524,92,888

19-Sep-2025

178.37

180.32178.37179.1111,33815,30,57,306.994,16,082

22-Sep-2025

179.01

179.1174174.2519,35819,68,48,767.926,60,229

23-Sep-2025

174.25

174.25169.97171.3222,43118,70,92,248.674,45,933

24-Sep-2025

171.34

172.47169.26170.0820,23314,91,58,878.464,81,724

25-Sep-2025

170.08

170.6168.51169.3911,29212,16,20,604.134,01,387

Marksans Pharma: Related NEWS

Marksans Pharma’s UK Subsidiary Relonchem Gets MHRA Approval for Moxonidine Tablets

In June, Relonchem also secured approval for oxybutynin hydrochloride oral solution, used in managing symptoms of an overactive bladder.

24 Sep 2025|09:58 AM
Read More
Marksans Pharma Secures EIR from USFDA for Subsidiary’s New York Facility

The inspection by the USFDA had taken place between April 16 and 24. After the visit, the company disclosed one observation under Form 483.

30 Jun 2025|05:57 PM
Read More
OrbiMed to Offload 2.27% Stake in Marksans Pharma via Block Deal

The block deal has been launched at a floor price of ₹249.95 per share, signaling a strategic partial exit by the investor.

11 Jun 2025|12:34 PM
Read More
Marksans Pharma’s Relonchem Gets UK MHRA Approval for Baclofen 10 mg

Relonchem Ltd has secured Marketing Authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Baclofen 10 mg Tablets

21 Mar 2025|12:02 PM
Read More
Marksans Pharma gets USFDA approval for anti-allergy drug

The US Food and Drug Administration (FDA) approved the pharmaceutical company's Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg.

22 Nov 2024|02:54 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.